Recent Finacing
Recent Raise
NeuBase Therapeutics develops a modular peptide-nucleic antisense oligonucleotide platform, PATrOL, for systemically deliverable therapeutics that target RNA secondary structures in repeat expansion disorders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at NeuBase Therapeutics.
